← Eichor
Study identifier: NCT06552676 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

riSk Factors fOR neCk phlEgmon afteR pErcutaneous tRacheostomy in ICU

Condition: Tracheostomy Complication · Quality of Life  ·  Sponsor: Azienda Usl di Bologna

PhaseN/A
Planned participants300
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Primary Purpose: To investigate the incidence and risk factors related to the appearance of tracheal phlegmon in patients undergoing percutaneous tracheostomy. Participant Population/Primary Condition: Patients admitted to Intensive Care Main Questions Aims to Answer: 1. \- What are the risk factors associated with the development of tracheal phlegmon percutaneous tracheostomy? 2. \- How does the appearance of tracheal phlegmon impact intensive care stay, hospital stay, mortality, and Health-related quality of life? Participants will be followed up after undergoing tracheostomy for 7 days to identify eventual phlegmons. At the two-year follow-up, the health-related quality of life will be assessed

This description comes directly from the study's public registry record.

Talk to the study team

Lorenzo Gamberini, MD  ·  +393403550540  ·  gamberini6@ausl.bologna.it

Always discuss trial participation with your own doctor first.

Locations (1)

Maggiore Hospital Carlo Alberto PizzardiBologna, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06552676